SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-26

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will evaluate the efficacy of targeted therapy based on tumor molecular profiling versus conventional chemotherapy in patients with advanced cancer using each patient as its own control. This study is a study involving patients with advanced cancer. All types of solid tumors will be allowed in the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

NCT01771458

Reccurent/Metastatic Solid Tumor Disease

COMPLETED PHASE2

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

NCT03515798

Inflammatory Breast Cancer

ACTIVE_NOT_RECRUITING PHASE2

Detect V / CHEVENDO (Chemo vs. Endo)

NCT02344472

Metastatic Breast Cancer

ACTIVE_NOT_RECRUITING PHASE3

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

NCT05594095

Breast Neoplasm Breast Cancer Hormone Receptor Positive Tumor +2 more

RECRUITING PHASE2

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

NCT04887870

Advanced or Metastatic Solid Malignancies

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Solid Tumor, Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

research of druggable molecular alterations on tumor biopsy

Group Type EXPERIMENTAL

research of druggable molecular alterations on tumor biopsy

Intervention Type DIAGNOSTIC_TEST

The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

research of druggable molecular alterations on tumor biopsy

The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion will proceed in 2 steps. First step for molecular analyses and second step in order to be included in the efficacy analysis.

1. Patient with recurrent/metastatic solid tumor who failed or are not candidate for treatments usually proposed in first intention and for whom a prospective clinical trial has been indicated in a tumor board
2. Patient with a documented progression before the start of conventional therapy according to RECIST 1.1.
3. Patient ≥18 years old

3\) Disease amenable to biopsy 5) ECOG performance status of 0 or 1 6) Measurable disease 7) Adequate renal function defined by a serum creatinine \<1.5xUNL (upper normal limit) 8) Adequate liver function test defined by SGOT \& SGPT \<3xUNL (5xUNL in case of liver metastases), and bilirubin level \<1.5xUNL 9) Adequate bone marrow function defined by platelets \>100,000/mm3, hemoglobin \>9 g/dL, and neutrophils \>1,000/mm3 10) Patient must be affiliated to the French Social Security System 11) Signed informed consent 12 For female of child-bearing potential: a negative pregnancy test \<72 hours before starting study treatment is required. If sexually active, female of childbearing potential must use "highly effective" methods of contraception for the study duration and for 3 months following the last treatment 13) For male of reproductive potential: any sexually active male patient must use a condom while on study treatment and for 3 months following the last treatment

1. Patient for whom the Molecular Biology Board (MBB) has identified a druggable molecular alteration of the RAF/MEK signaling pathway and a treatment recommendation has been established by the MBB.
2. Patient with a documented progression during the conventional therapy according to RECIST 1.1.
3. Patient with imaging performed within 28 days prior to the planned start date of treatment

Exclusion Criteria

1. Patients below 18 years old
2. Patients with CNS involvement that has not been controlled for \>3 months
3. Patients planned to receive a molecularly targeted agent
4. Patients who are candidate to receive a molecularly targeted agent that is approved for their disease
5. Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, including uncontrolled diabetes, cardiac disease, uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infection within one year, chronic liver or renal disease, active gastrointestinal tract ulceration, severely impaired lung function
6. Pregnant and/or breastfeeding women
7. Patients individually deprived of liberty or placed under the authority of a tutor
8. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
9. Known HIV, HBV, or HCV infection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No